News


Announcement – AroCell AB PR and Marketing Communications Manager

AroCell AB has signed an agreement today with Kris Rydholm Överby, who will be reinforcing the management group in the role of PR and Marketing Communications Manager. 

Kris Rydholm Överby is originally from the United States, and has an educational background in international marketing and business administration from the University of Wisconsin. She moved to Sweden in the early 1980’s where she has held extensive global product and marketing manager positions and generated many award-winning marketing communications projects and campaigns. She is a well-known Life Science marketing profile in Sweden and the United States.

Kris is also a CMPP certified medical writer and was Editor-in-Chief of Maquet Critical Care News for 6 years where she produced customer interviews, patient case reports and other peer-to-peer clinical educational materials.

“We are delighted to welcome Kris Rydholm Överby to the AroCell team” says Jan Stålemark, CEO. “She has a unique life science marketing background, with international and US domestic market perspectives, and as a medical writer we will benefit from her experience in developing peer-to-peer educational materials in line with our clinical development”.

 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
AroCell announcement Dec 19 2016

 

Ann Hammarstrand appointed as new CFO to AroCell

AroCell AB (publ) announces today that Ann Hammarstrand has been appointed as Chief Financial Officer to AroCell, effective beginning of 2017. She will be replacing Bengt Norvik, who is leaving the company to pursue other opportunities.

Ann Hammarstrand has an extensive and comprehensive background as CFO in other industries within the Life Science and financial audit sectors. Ann worked as Certified Public Accountant in the firm of PwC. In 2000, Ann joined Radi Medical Systems in Uppsala, acquired by St Jude Medical Systems in 2009, as Chief Financial Officer.

Since leaving St Jude Medical Systems in 2013, Ann has worked at the County Council of Uppsala in governance and management issues as well as operational development.

– I am pleased to welcome Ann Hammarstrand to AroCell as Chief Financial Officer, says Jan Stålemark, AroCell CEO. Her extensive financial background and global experience within the Life Science industry as CFO and Director of Finance will significantly augment not only our management team but also our business operations in the future. I also want to thank Bengt Norvik sincerely for all his contributions to the company during his time with us and wish all the success in his future endeavours.

For additional information:
Jan Stålemark, CEO AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark, at 16:20 CET on 3 November 2016. 

About AroCell AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,700 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser.

The News in PDF

AroCell signs distribution agreement with Eagle Biosciences in the United States

AroCell AB (publ) announced today that a distribution agreement has been signed with the New England-based company Eagle Biosciences, for distribution of the AroCell TK 210 ELISA test in North America.

The TK 210 ELISA test measures TK1 protein levels for valuable information about the speed of cell turnover. As tumors have high cell turnover, the test may provide valuable information for prognosis and optimization of treatment strategy.

“We are delighted to partner with Eagle Biosciences for the distribution of the TK 210 ELISA test”, states Jan Stålemark, AroCell CEO. “Eagle Biosciences is a leading provider of ELISA assay kits in North America, and has primary focus on providing innovative products that aid medical research and clinical laboratories. This highly concurs with our strategy to make the TK 210 ELISA test widely available for investigational use in the US, in order to facilitate use of the product in cancer research institutions as well as within the pharmaceutical industry”.

The TK 210 ELISA test will be commercially available immediately through Eagle Biosciences for investigational use only in the United States.

 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

 

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through Jan Stålemark, at 11:45 CET on 6th October 2016. Redeye is AroCell:s Certified Adviser

 

arocell_press_release_oct_6_2016_eagle_biosciences

arocell_pressmeddelande_6_okt_2016_eagle_biosciences

Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.

Thymidine Kinase 1 (TK1) is a key enzyme in DNA synthesis and it is produced by and released into the blood from proliferating cells, especially tumor cells. It is a well-studied biomarker for studying tumor growth.

TK1 levels in the blood of healthy subjects are very low, requiring sensitive assays. When developing such assays, establishing the zero calibrator, or blank, value is a key point as it determines the limit of sensitivity.

ArOCell has redesigned the preparation of the zero Calibrator in its TK 210 ELISA kit, replacing the current human serum based material with a proprietary buffer-based Calibrator. The benefit of the change is better discrimination of TK1 values in samples with low-normal values. The performance of the Arocell TK 210 ELISA with the new zero calibrator in healthy subjects will be presented by Dr. Kiran Kumar Jagarlamudi, clinical research manager at AroCell at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) in Chicago next month, September 4th.

We are pleased that we have improved the TK 210 ELISA, but one should keep in mind that establishment of the value of this increased sensitivity and discrimination will require further studies including material from subjects with known pathologies says Jan Stålemark, CEO at AroCell.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through Jan Stålemark, at 16:58 CET on 12 August 2016. Redeye is AroCell:s Certified Adviser.

Nyheten i PDF

AroCell is approved for listing on the Nasdaq First North and publishes Corporate description

AroCell AB (publ) has been accepted for trading on Nasdaq First North. The last day of trading on AktieTorget is the 29 June 2016 and the first day of trading on Nasdaq First North is the 30 June 2016.

AroCell will continue to be traded under the ticker symbol AROC with current ISIN code SE0003883990. Redeye AB will act as the company’s Certified Adviser on First North. The company has established a corporate description approved by Nasdaq First North, which from today is available on the AroCells website, www.arocell.com.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.

The News in PDF
Nyheten i PDF.

 

AroCell applying for listing on the Nasdaq First North exchange

The Board of Directors of AroCell AB (publ) have decided to apply for listing of the company shares to trading on the Nasdaq First North exchange, and thereby change market for share listing.

The change of market listing is planned to take place at the turn of the month June/July 2016, and the first date for trading will be announced after approval from the Nasdaq First North exchange.

“The assessment of the Board and Management is that Nasdaq First North is a market exchange that will provide a broader exposure of the company to more groups of investors and institutions. It will also provide better opportunities for foreign investors to trade in company shares by means of the more international profile and accessibility of the Nasdaq First North exchange”, says AroCell CEO Jan Stålemark.

Redeye AB has been appointed as advisor in connection with the change of market listing.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com


About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.

The Press Release in PDF
Pressmeddelandet i PDF

Christine Tadgell new board member in AroCell

Christine Tadgell has been elected as board member in AroCell AB (publ) at the Annual General Meeting on May 18, 2016

Christine Tadgell received a Bachelor of Science degree at Concordia University, Montreal, Quebec, Canada. She is currently Vice-President for the inVentiv Health European Commercial Group situated in London, UK. She has a background within the area of biopharmaceuticals and international experience from Europe and North America, as well as extensive experience of commercial strategy within the pharmaceutical industry.

-The competence within the board will be additionally reinforced by Christine Tadgells international experience and knowledge. Christine Tadgell will be a strong resource in the continued company development, states Jan Stålemark, AroCell CEO. 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

About AroCell AB (publ) AroCell is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.

The News in English, pdf

The News in Swedish, pdf

 

 

Leading profile in biomarkers joins the AroCell management team

AroCell AB announces the addition of Martin Shaw as Business Development Manager to the management team. Martin Shaw has over 40 years’ experience in the development and introduction of novel biomarker assays, to the pharmaceutical, biotechnology and laboratory medicine industries.

Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson.

From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation.

Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies.

Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.

“We are pleased and proud to announce the addition of Martin Shaw as Business Development Manager to the AroCell team” states Jan Stålemark, CEO AroCell AB. “I am convinced that his extensive experience in biomarker assays, and deep knowledge of the clinical laboratory and biomarker industries will contribute significantly to the clinical establishment of our TK 210 ELISA test”.

 

See pdf of the press release in Engish

See pdf of the press release in Swedish

For further information:

Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206

info@arocell.com
www.arocell.com

 

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB is listed at AktieTorget (AROC) and has about 2 300 shareholders.

New patent strengthens the AroCell patent portfolio

The European Patent Office has confirmed the grant of a patent to AroCell AB regarding an invention relating to exposed thymidine kinase 1 (TK1) derived peptides, ligands and methods employing these.

“We are delighted to hear that the European Patent Office has granted us this patent regarding exposed proliferation related peptides”, states Jan Stålemark, AroCell CEO. “This latest patent provides us with an additional level of protection for our unique TK 210 ELISA test, as we continue to establish the clinical validation of our product”.

For further information:

Jan Stålemark, CEO
AroCell AB (pub)
Tel: +46-706926206

info@arocell.com
www.arocell.com

 

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB is listed at AktieTorget (AROC) and has about 2 300 shareholders.

This press release in English, PDF
This press release in Swedish, PDF

New clinical study with promising results for the TK 210 ELISA test from AroCell

This study published in the journal Tumor Biology, included 124 breast cancer patients with known TNM classification and known values of the well-established breast cancer biomarker CA 15-3. Additionally, 53 healthy individuals were also included in the study, where serum samples were analyzed with the AroCell TK 210 ELISA test, which measures TK1 protein levels. Results demonstrated that the TK 210 ELISA test showed significantly higher sensitivity compared to the TK1 activity test with serum samples from breast cancer patients, particularly with patients in early stages of disease.

“We are pleased and proud to announce the results of our TK 210 ELISA test in this breast cancer study” states Jan Stålemark, AroCell CEO. “Furthermore, this study established that combinational approach of TK 210 ELISA test with CA 15-3 significantly increased the diagnostic sensitivity. These fundamental results are proof that our CE-marked TK 210 ELISA test works in clinical application and can provide important information to oncologists during the course of treatment. These results are important for the continued clinical validation of our test to achieve broad clinical acceptance”.

Link to the full article published online 14 April 2016

For further information:
Jan Stålemark, CEO
AroCell AB (pub)
Pho: +46-706 926 206
info@arocell.com
www.arocell.com

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell is listed at AktieTorget (AROC) and has about 2 800 shareholders.

PDF of this press release in English
PDF of this press release in Swedish

Final call for trading with BTA

During the month of December 2015 AroCell AB (publ) conducted a preferential rights issue. The last day for trading with BTA will take place on January 12th 2016 and the stop day is January 14th 2016. BTA’s will be converted to shares January 18th 2016.

After the preferential rights issue the share capital will be 2 867 450,60 SEK distributed on 28 674 506 shares.

Redeye AB is the financial advisor for the preferential rights issue in collaboration with Corpura AB. Legal advisor is Fredersen Advokatbyrå AB.

For more information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706-926206
info@arocell.com
www.arocell.com

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. AroCell AB (AROC) is listed at AktieTorget and has about 2 300 shareholders.

Final call for trading with BTA, PDF
Final call for trading with BTA in Swedish, PDF